Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
61 studies found for:    hypercoagulation OR thrombophilia OR blood clotting | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
22 Recruiting Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Condition: HIV-1 Infection
Intervention: Drug: Telmisartan
23 Recruiting Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
Condition: Acute Deep Vein Thrombosis
Interventions: Other: Exercise;   Other: Control
24 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
25 Recruiting Platelet Activity in Vascular Surgery and Cardiovascular Events
Conditions: Cardiovascular Disease;   Peripheral Artery Disease;   Critical Limb Ischemia
Intervention:
26 Recruiting The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
Condition: Gonorrhoea
Interventions: Drug: Cefixime;   Drug: Azithromycin
27 Recruiting Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort
Conditions: HIV Infection;   Alcohol Use
Interventions: Dietary Supplement: Zinc gluconate;   Dietary Supplement: Placebo
28 Recruiting Study of Procoagulation Markers in Stroke Patients
Conditions: Stroke;   Hyperglycemia;   Procoagulation Markers
Intervention: Other: Glycemic Control
29 Recruiting Chronology of Occult and Gross Coagulopathy in Burn Patients
Condition: Thermal Burns
Intervention:
30 Recruiting Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol
Condition: Healthy Volunteers
Intervention:
31 Recruiting Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)
Condition: Healthy
Interventions: Biological: Thrombosomes;   Biological: Placebo
32 Recruiting Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
Condition: HIV-1 Infection
Intervention: Drug: Isotretinoin
33 Unknown  Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Sleep Disorder
Interventions: Drug: Eszopiclone;   Other: Placebo
34 Recruiting CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Condition: Previously Treated Myelodysplastic Syndromes
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
35 Recruiting Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies
Conditions: Blood Component Removal;   Human Immunodeficiency Virus
Intervention:
36 Recruiting Whole Blood and Blood Component Collection for Research
Conditions: Blood Donors;   Research Subjects;   Apheresis
Intervention:
37 Not yet recruiting Cancer Associated Thrombosis and Isoquercetin (CAT IQ)
Conditions: Thromboembolism of Vein VTE in Colorectal Cancer;   Thromboembolism of Vein in Pancreatic Cancer;   Thromboembolism of Vein in Non-small Cell Lung Cancer
Intervention: Drug: Isoquercetin
38 Recruiting Development of Computer-aided Detection and Diagnosis From Imaging Techniques
Condition: Cancer
Intervention:
39 Recruiting A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: NY-ESO-1 157-165 (165V);   Drug: Nivolumab;   Biological: gp100:280-288 (288V);   Drug: Montanide ISA 51 vegetable grade (VG);   Drug: Ipilimumab;   Procedure: Apheresis Procedure
40 Recruiting Participation in a Research Registry for Immune Disorders
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Wiskott- Aldrich Syndrome;   Primary Immunodeficiencies;   Severe Combined Immune Deficiency
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years